FY2025 Earnings Estimate for Curaleaf Issued By Cormark

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Equities researchers at Cormark decreased their FY2025 EPS estimates for Curaleaf in a research report issued to clients and investors on Wednesday, March 5th. Cormark analyst J. Pytlak now expects that the company will earn ($0.23) per share for the year, down from their previous estimate of ($0.19). The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Cormark also issued estimates for Curaleaf’s FY2026 earnings at ($0.16) EPS.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Monday, March 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.09. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%. The business had revenue of $331.05 million during the quarter, compared to analysts’ expectations of $331.87 million.

Curaleaf Stock Performance

Shares of CURLF opened at $0.96 on Monday. Curaleaf has a 12 month low of $0.88 and a 12 month high of $6.40. The firm has a fifty day simple moving average of $1.38 and a 200 day simple moving average of $2.10. The stock has a market capitalization of $634.20 million, a price-to-earnings ratio of -3.31 and a beta of 0.57. The company has a current ratio of 1.11, a quick ratio of 0.51 and a debt-to-equity ratio of 0.85.

About Curaleaf

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.